Companies Investors People

Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

Contact
Request a Demo
Request Data Updates
Add a Company

Research

Companies
Investors
People

aVenture

Download App
Pricing

Resources

Documentation
Use Cases
CLI
MCP
Feature Requests
Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading

John Flavin - aVenture Research

John Flavin

AddedMar 31, 2024

UpdatedOct 16, 2026

John Flavin

John Flavin

Founder & CEO, Portal Innovations

John Flavin's Career

Portal Innovations

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview

aVenture product preview

aVenture product preview

Investment FirmChicago, IL, US

Founder & CEO· C-Suite · Management

Founder

ClostraBio

Series A$7.5MChicago, IL, US

Board Member· Board

Tract Therapeutics

Series B$15MChicago, IL, US

CEO· C-Suite · Management

Grove Biopharma

Seed$10.5MChicago, IL, US

Board Member· Board

People Similar to John Flavin

Brian AtwoodCo-Founder · Versant Ventures

Bruce BeutelBoard Member · Boston Immune Technologies & Therapeutics

Christopher RobertsCEO · Civetta Therapeutics

Similar to Portal Innovations

BioInnovationCambridge, MA, USest. 2016BioInnovationCambridge, MA, US · est. 2016

BioInnovation LLC: A Cambridge-based life sciences firm investing in, co-founding, and nurturing early-stage ventures.

Investment Firm5

BioCrossroadsIndianapolis, IN, USest. 2002BioCrossroadsIndianapolis, IN, US · est. 2002

BioCrossroads: A life sciences growth assistant providing financing, education, and networking in Indiana.

Investment Firm16

InVivium CapitalChicago, IL, USInVivium CapitalChicago, IL, US

Chicago-based InVivium Capital, a financial services firm specializing in healthcare and life sciences investments.

Investment Firm7

Emerald BioventuresNew York City, NY, USEmerald BioventuresNew York City, NY, US

NYC-based venture capital firm specializing in incubating life science, biotech, and health tech companies.

Investment Firm30

Leadership at ClostraBio

Cathryn NaglerCo-Founder

Jeffrey A HubbellCo-Founder

Similar to ClostraBio

Microbiome TherapeuticsBroomfield, CO, USMedical Researchest. 2009Microbiome TherapeuticsBroomfield, CO, US · est. 2009

Microbiome Therapeutics LLC: A US-based medical research firm specializing in metabolic disease solutions.

Series B · $3M30

Petri BioLos Angeles, CA, USTherapeuticsest. 2019Petri BioLos Angeles, CA, US · est. 2019

Petri Bio: A biotech firm innovating gut microbe-based therapeutics.

MarvelBiomeWoburn, MA, USTherapeuticsest. 2019MarvelBiomeWoburn, MA, US · est. 2019

MarvelBiome: A biopharmaceutical company harnessing microbial power for innovative disease treatments.

Vedanta BiosciencesCambridge, MA, USBiotechest. 2010Vedanta BiosciencesCambridge, MA, US · est. 2010

Vedanta Biosciences: An American biotech firm pioneering microbiome immune system drugs for immune diseases.

Series E · $433.1M116

Leadership at Tract Therapeutics

Gretchen S JohnsonCo-Founder

Joseph LeventhalCo-Founder

Similar to Tract Therapeutics

Tr1xLos Angeles, CA, USCell Therapyest. 2018Tr1xLos Angeles, CA, US · est. 2018

Tr1x: Pioneering cellular therapies for autoimmune disorders, recalibrating the immune system for long-term tolerance.

Series A · $75M30

Sonoma BiotherapeuticsSouth San Francisco, CA, USTreg Therapiesest. 2020Sonoma BiotherapeuticsSouth San Francisco, CA, US · est. 2020

Sonoma Biotherapeutics: Pioneering Treg cell therapies for autoimmune and inflammatory diseases.

Series C · $365M146

Abata TherapeuticsCambridge, MA, USTreg Therapiesest. 2021Abata TherapeuticsCambridge, MA, US · est. 2021

Abata Therapeutics: Pioneering Treg-engineered therapies for autoimmune diseases.

Series A · $95M57

TregTherapeuticsChapel Hill, NC, USVaccineest. 2018TregTherapeuticsChapel Hill, NC, US · est. 2018

TregTherapeutics, a preclinical-stage company, develops a novel vaccine for multiple sclerosis treatment, leveraging Treg cells' power to alter autoimmune disease outcomes.

Angel · $250k6

Leadership at Grove Biopharma

Geoffrey M. DuykCo-Founder

Paul BertinCo-Founder

Similar to Grove Biopharma

GRO BiosciencesBoston, MA, USProtein Therapeuticsest. 2016GRO BiosciencesBoston, MA, US · est. 2016

GRO Biosciences innovates protein therapeutics using novel amino acids to combat incurable diseases.

Series A · $32.3M44

Groove BiopharmaSeattle, WA, USDrugs, Therapeuticsest. 2008Groove BiopharmaSeattle, WA, US · est. 2008

Groove Biopharma: Pioneering microRNA therapeutics for cancer, fibrosis, and infectious diseases.

Series B · $9.9M6

Orange Grove BioCincinnati, OH, USDrug Discoveryest. 2019Orange Grove BioCincinnati, OH, US · est. 2019

OGB: A preclinical biotech platform advancing affordable drug discovery and clinical trials.

Series B · $18.6M35

ProFound TherapeuticsCambridge, MA, USTherapeuticsest. 2022ProFound TherapeuticsCambridge, MA, US · est. 2022

ProFound Therapeutics: Innovating impactful disease understanding and therapeutic creation.

Series A · $75M35